Abstract
The Liver X Receptors LXRα and LXRβ are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. Seminal studies with genetic and chemical tools were instrumental in the elucidation of cholesterol metabolism, gluconeogenesis, inflammation, and lipogenesis as signaling pathways that are controlled by the LXRs. First generation non-steroidal LXR agonists show beneficial effects in multiple animals models of human disease yet have not progressed in the clinic due to deleterious side effects in the liver. Numerous reports have appeared in the the recent literature that disclose new LXR signaling pathways and the identication of novel LXR chemotypes that may show improved therapeutic indices. This review will provide a brief historical perspective but will primarily focus on recent advances in LXR biology and chemistry.
Keywords: Liver X receptors, LXR chemotypes, LXR crystal structure, LXR therapeutic indications
Current Topics in Medicinal Chemistry
Title: Recent Advances in Liver X Receptor Biology and Chemistry
Volume: 8 Issue: 9
Author(s): Bryan J. Goodwin, William J. Zuercher and Jon L. Collins
Affiliation:
Keywords: Liver X receptors, LXR chemotypes, LXR crystal structure, LXR therapeutic indications
Abstract: The Liver X Receptors LXRα and LXRβ are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. Seminal studies with genetic and chemical tools were instrumental in the elucidation of cholesterol metabolism, gluconeogenesis, inflammation, and lipogenesis as signaling pathways that are controlled by the LXRs. First generation non-steroidal LXR agonists show beneficial effects in multiple animals models of human disease yet have not progressed in the clinic due to deleterious side effects in the liver. Numerous reports have appeared in the the recent literature that disclose new LXR signaling pathways and the identication of novel LXR chemotypes that may show improved therapeutic indices. This review will provide a brief historical perspective but will primarily focus on recent advances in LXR biology and chemistry.
Export Options
About this article
Cite this article as:
Goodwin J. Bryan, Zuercher J. William and Collins L. Jon, Recent Advances in Liver X Receptor Biology and Chemistry, Current Topics in Medicinal Chemistry 2008; 8 (9) . https://dx.doi.org/10.2174/156802608784535075
DOI https://dx.doi.org/10.2174/156802608784535075 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Normal and Pathologic Roles of the Alzheimer's β-secretase, BACE1
Current Alzheimer Research Breast Cancer Stem Cells and Intrinsic Subtypes: Controversies Rage On
Current Stem Cell Research & Therapy Recent Developments in CE-MS Based Metabolomics
Current Analytical Chemistry NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Multidrug Transporters as Drug Targets
Current Drug Targets Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair
CNS & Neurological Disorders - Drug Targets Autophagy Enhancer Carbamazepine Alleviates Memory Deficits and Cerebral Amyloid-β Pathology in a Mouse Model of Alzheimer's Disease
Current Alzheimer Research A New Aspect of the TrkB Signaling Pathway in Neural Plasticity
Current Neuropharmacology Extracellular ATP and Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders Role of Tumor Microenvironment in Cancer Stem Cells Resistance to Radiotherapy
Current Cancer Drug Targets Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC) ?
Current Cancer Therapy Reviews Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Current Medicinal Chemistry Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets Small Molecule Inhibitors of Peptidylprolyl cis/trans Isomerase
Current Enzyme Inhibition Advanced Membrane Systems for Tissue Engineering
Current Organic Chemistry Natural Compounds and Drug Discovery: Can Cnidarian Venom Play a Role?
Central Nervous System Agents in Medicinal Chemistry Applications of Gene Transfer to Targeted Radiotherapy
Current Pharmaceutical Design Death Receptor Signaling in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation
Current Cancer Drug Targets Polysialyltransferase: A New Target in Metastatic Cancer
Current Cancer Drug Targets